Background/aim: Infection is a common cause of morbidity and mortality in patients treated for diffuse large B-cell lymphoma (DLBCL). However, there is limited information on the impact and risk factors for infection among patients receiving rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP).

Patients And Methods: A retrospective study evaluating patients with DLBCL receiving R-CHOP and R-COP between 2004 and 2021 was conducted at a medical center. Hospital patients' records for the five-item modified frailty index (mFI-5), sarcopenia, blood-based inflammatory markers, and clinical outcomes were statistically analyzed.

Results: Patients with frailty, sarcopenia, and high neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of infections. The revised International Prognostic Index poor-risk group, high NLR, infections, and treatment modality were risk factors for shorter progression-free and overall survival.

Conclusion: Pre-treatment high NLR was a predictor of infection and survival outcome in DLBCL patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026672PMC
http://dx.doi.org/10.21873/invivo.13167DOI Listing

Publication Analysis

Top Keywords

neutrophil-to-lymphocyte ratio
8
infection survival
8
diffuse large
8
risk factors
8
high nlr
8
patients
5
association neutrophil-to-lymphocyte
4
infection
4
ratio infection
4
survival diffuse
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!